For following the competition: what moved in each program, several studies read as one move.
- BRL-301
- Targeted BCMA Gene-Modified Allogeneic Chimeric Antigen Receptor T-Cell Injection
Mondays · ranked, phase 3 first · readouts ahead · See a sample brief
Add BRL Medicine to watchlistEvery Monday by email · turn it off any timePro · free during the beta